LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

Home・Elenco Azioni・Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Inc

Chiusa

SettoreSettore sanitario

21.45 0.28

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

20.79

Massimo

21.51

Metriche Chiave
By Trading Economics
Entrata	-29M -11M
Vendite	-24M 105M
EPS	-0.09
Margine di Profitto	-10.717
Dipendenti	354
EBITDA	-31M -8.5M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+62.44% upside

Dividendi
By Dow Jones
Utili prossimi	5 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-329M 2.6B
Apertura precedente	21.17
Chiusura precedente	21.45

Notizie sul Sentiment di mercato

By Acuity

67%

33%

283 / 344 Classifica in Healthcare

Arcutis Biotherapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

31 mag 2026, 23:44 UTC

Discorsi di Mercato

Nikkei May Remain Rangebound Amid Middle East Uncertainty -- Market Talk

31 mag 2026, 23:36 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

31 mag 2026, 23:36 UTC

Discorsi di Mercato

Oil Rises Amid Few Signs of Strait of Hormuz's Reopening -- Market Talk

31 mag 2026, 23:36 UTC

Discorsi di Mercato

Watch for Data-Center Investment in Australia's 1Q GDP Print -- Market Talk

31 mag 2026, 22:54 UTC

Acquisizioni, Fusioni, Takeovers

Berkshire Hathaway to Buy Homebuilder Taylor Morrison for $6.8 Billion -- WSJ

29 mag 2026, 23:08 UTC

Acquisizioni, Fusioni, Takeovers

Family Offices Bypass Private Equity and Go Direct -- Barrons.com

29 mag 2026, 23:06 UTC

Acquisizioni, Fusioni, Takeovers

After a Series of Sales, Hims Director Buys Company Shares -- Barrons.com

29 mag 2026, 20:53 UTC

Utili

Oil Declines Lift Stocks to Fresh Records -- WSJ

29 mag 2026, 20:50 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

29 mag 2026, 20:33 UTC

Discorsi di Mercato

Canada Meets Only One of Three Criteria To Declare Recession -- Market Talk

29 mag 2026, 20:11 UTC

Utili

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29 mag 2026, 19:47 UTC

Utili

These Were the Best and Worst S&P 500 Stocks in May -- Barrons.com

29 mag 2026, 19:36 UTC

Discorsi di Mercato

U.S. Natural Gas Futures End Month With Gains -- Market Talk

29 mag 2026, 19:34 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

29 mag 2026, 19:34 UTC

Discorsi di Mercato

Over Half of Canadian Industries Growing, Undermining Recession Talk -- Market Talk

29 mag 2026, 19:22 UTC

Discorsi di Mercato

Oil Falls as U.S., Iran Expected to Reach Agreement -- Market Talk

29 mag 2026, 19:05 UTC

Acquisizioni, Fusioni, Takeovers

Universal Music Group Rejects $65 Billion Takeover Bid From Bill Ackman's Pershing Square -- Barrons.com

29 mag 2026, 18:19 UTC

Discorsi di Mercato

Canada Technical Recession Chatter Rife But Per-Capita GDP Was Up -- Market Talk

29 mag 2026, 18:12 UTC

Acquisizioni, Fusioni, Takeovers

Universal Music Group Rejects $65 Billion Buyout Offer From Bill Ackman -- WSJ

29 mag 2026, 18:11 UTC

Discorsi di Mercato

Canada Households Reaching Limit at Keeping Spending in Positive Territory -- Market Talk

29 mag 2026, 18:10 UTC

Discorsi di Mercato

As BTC Long-Term Holders Rise, Short-Term Holders Flee -- Market Talk

29 mag 2026, 17:55 UTC

Utili

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29 mag 2026, 17:55 UTC

Discorsi di Mercato

NEAR Protocol Nearly Doubles in May -- Market Talk

29 mag 2026, 17:38 UTC

Discorsi di Mercato

U.S. Oil Rig Count Rises for Fifth Straight Week -- Market Talk

29 mag 2026, 17:00 UTC

Utili

Okta Stock Soars After Earnings. Results Aren't the Real Catalyst. -- Barrons.com

29 mag 2026, 16:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

29 mag 2026, 16:20 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

29 mag 2026, 16:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

29 mag 2026, 16:02 UTC

Discorsi di Mercato

Gold Extend Gains as Investors Await U.S.-Iran Deal News -- Market Talk

29 mag 2026, 15:55 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

Confronto tra pari

Modifica del prezzo

Arcutis Biotherapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

62.44% in crescita

Previsioni per 12 mesi

Media 34.86 USD 62.44%

Alto 36 USD

Basso 34 USD

Basato su 7 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Arcutis Biotherapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

7 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 7 che hanno fornito valutazioni azionarie a Arcutis Biotherapeutics Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

283 / 344 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.